Mitochondrial Complex II (Succinate Dehydrogenase)

📖 Wiki Page

mechanism1312 wordssynced 2026-04-02

Mitochondrial Complex II (Succinate Dehydrogenase)

Introduction

Mitochondrial Complex Ii (Succinate Dehydrogenase) is an important component in the neurobiology of neurodegenerative diseases. This page provides detailed information about its structure, function, and role in disease processes.

Mitochondrial Complex II, also known as Succinate Dehydrogenase (SDH) or Complex II, is a unique enzyme that functions in both the Electron Transport Chain (ETC) and the Citric Acid Cycle (TCA Cycle). It catalyzes the oxidation of succinate to fumarate in the TCA cycle while simultaneously transferring electrons to coenzyme Q (ubiquinone) in the ETC. Unlike Complexes I, III, and IV, Complex II does not pump protons across the inner mitochondrial membrane. [@rustin2002]

Complex II (Succinate Dehydrogenase) Pathway

flowchart TD A["Succinate (Substrate)"] --> B["Complex II (SDH)"] B --> C["FAD Reduction"] C --> D["Electron Transfer to CoQ"] D --> E["Ubiquinol Generation"] E --> F["Complex III Entry"] B --> G["Complex II Dysfunction"] G --> H["ROS Overproduction"] H --> I["Oxidative Neuronal Damage"] I --> J["Neurodegeneration (HD/PD)"]

Overview

...

Mitochondrial Complex II (Succinate Dehydrogenase)

Introduction

Complex II (Succinate Dehydrogenase) Pathway

Mermaid diagram (expand to render)

Overview

Complex II represents a critical link between carbohydrate metabolism and oxidative phosphorylation. It is one of only two ETC complexes that are entirely nuclear-encoded (the other is Complex II's partner in the TCA cycle). The enzyme's dual role makes it essential for cellular energy metabolism, and its dysfunction has been implicated in various neurodegenerative diseases, metabolic disorders, and cancers. [@ackrell2001]

Structure

Complex II is composed of four subunits that form a heterotetramer: [@sun2005]

Water-Soluble Catalytic Domain (Matrix-facing)

SDHA (Flavoprotein, 70 kDa): Contains the FAD cofactor and the substrate-binding site. SDHA undergoes conformational changes during catalysis and is the site of succinate oxidation.
SDHB (Iron-Sulfur Protein, 30 kDa): Contains three different iron-sulfur clusters 2Fe-2S, 4Fe-4S, and 3Fe-4S that serve as electron conduits between FAD and ubiquinone.

Membrane-Anchoring Domain (Integral membrane)

SDHC (15 kDa): Anchors the complex to the inner mitochondrial membrane
SDHD (12 kDa): Works with SDHC to anchor the complex and provide the ubiquinone-binding site

Prosthetic Groups

FAD (Flavin Adenine Dinucleotide): Covalently attached to SDHA, essential for succinate oxidation
2Fe-2S cluster: First electron transfer site in SDHB
4Fe-4S cluster: Second electron transfer site
3Fe-4S cluster: Third electron transfer site
Ubiquinone-binding site: Located at the interface of SDHC/SDHD

Function

Catalytic Activity

Complex II catalyzes two interconnected reactions: [@rutter2010]

TCA Cycle Reaction (Oxidation):

Succinate + FAD → Fumarate + FADH2

Succinate binds to the FAD-containing SDHA subunit
Two electrons are transferred through the iron-sulfur clusters to ubiquinone
FAD is regenerated as fumarate is released

Electron Transport Chain Reaction:

FADH2 + CoQ (oxidized) → FAD + CoQH2 (reduced)

Electrons from FADH2 are transferred through SDHB's iron-sulfur clusters
Finally transferred to ubiquinone in the inner mitochondrial membrane
Reduced ubiquinol (CoQH2) then transfers electrons to Complex III

Key Characteristics

No proton pumping: Unlike other ETC complexes, Complex II does not contribute to the proton gradient
FADH2 production: Generates FADH2 that enters the ETC at Complex II level (~1.5 ATP equivalent)
Bidirectional: Can also work in reverse under certain conditions (fumarate reduction)
TCA cycle integration: Links succinate oxidation to the respiratory chain

Regulation

Transcriptional Regulation

PPARGC1A/PGC-1α: Master regulator of mitochondrial biogenesis, including SDH expression
NRF1/NRF2: Nuclear respiratory factors affect SDH subunit expression
Hypoxia-inducible factors (HIF): SDHB and SDHD are HIF targets

Post-Translational Regulation

Phosphorylation: SDHA can be phosphorylated, affecting activity
Acetylation: Metabolic status influences SDH acetylation
O-GlcNAcylation: Glucose metabolism affects SDH modification

Allosteric Regulation

Product inhibition: Fumarate and succinate analogs can inhibit activity
ATP/ADP ratio: Energy status affects SDH function

Neurodegeneration Relevance

Leigh Syndrome

Complex II deficiency causes a severe form of Leigh syndrome: [@wallace1999]

SDHAF1/SDHAF2 mutations: Assembly factor defects cause SDH deficiency
SDHA mutations: Rare recessive mutations cause severe encephalopathy
Clinical features: Rapidly progressive neurodegeneration, lactic acidosis, bilateral basal ganglia lesions
Pathogenesis: Energy failure due to impaired oxidative phosphorylation

Hereditary Paraganglioma-Pheochromocytoma Syndrome

Germline mutations in SDHD, SDHC, and SDHB predispose to tumors: [@browne1999]

SDHD mutations: Most common, usually benign head and neck paragangliomas
SDHB mutations: Higher malignancy risk
SDHC mutations: Rare, usually benign
Inheritance: Autosomal dominant with parent-of-origin effects
Mechanism: Pseudohypoxia due to impaired SDH function

Huntington's Disease (HD)

Complex II dysfunction is a key feature of HD: [@gu1998]

Reduced SDH activity: Post-mortem studies show decreased Complex II activity in the striatum
Selective vulnerability: Medium spiny neurons are particularly affected
Mutant [huntingtin](/proteins/huntingtin) effects: Direct and indirect impairment of mitochondrial function
Bioenergetic failure: Contributes to the characteristic neurodegeneration
Therapeutic target: SDH modulators have been explored as potential treatments

Alzheimer's Disease (AD)

Variable changes: Complex II activity can be altered in AD
Metabolic dysfunction: Contributes to overall mitochondrial impairment
TCA cycle disruption: Links to broader metabolic dysfunction in AD

Parkinson's Disease (PD)

Secondary effects: Complex II can be affected by Complex I dysfunction
mtDNA interactions: May contribute to dopaminergic neuron vulnerability
[α-Synuclein](/proteins/alpha-synuclein) effects: Oligomeric α-synuclein may impair SDH function

Amyotrophic Lateral Sclerosis (ALS)

Motor neuron vulnerability: High energy demands make motor neurons susceptible
Complex II deficiency: Reported in some ALS models and patient tissue
Energy metabolism: Contributes to motor neuron degeneration

Therapeutic Implications

Potential Therapeutic Strategies

Coenzyme Q10 (CoQ10): May improve electron transfer

Vitamin K2: May support SDH function

Metabolic modulators: Compounds targeting succinate metabolism

Gene therapy: Potential for delivering wild-type SDH genes

Small molecule activators: SDH activity enhancers under investigation

Challenges

SDH is entirely nuclear-encoded, but mutations can cause severe disease
Tumor syndromes require careful management
Limited understanding of CNS-directed therapies

Background

The study of Mitochondrial Complex Ii (Succinate Dehydrogenase) has evolved significantly over the past decades. Research in this area has revealed important insights into the underlying mechanisms of neurodegeneration and continues to drive therapeutic development. [@lin2006]

Historical context and key discoveries in this field have shaped our current understanding and will continue to guide future research directions. [@paschen2012]

External Links

[PubMed](https://pubmed.ncbi.nlm.nih.gov/) - Biomedical literature
[Alzheimer's Disease Neuroimaging Initiative](https://adni.loni.usc.edu/) - Research data
[Allen Brain Atlas](https://brain-map.org/) - Brain gene expression data

Additional evidence sources: [@ricketts2021] [@bayley2010]

Confidence Assessment

🔴 Low Confidence

| Dimension | Score |
|-----------|-------|
| Supporting Studies | 12 references |
| Replication | 0% |
| Effect Sizes | 25% |
| Contradicting Evidence | 0% |
| Mechanistic Completeness | 50% |

Overall Confidence: 34%

Recent Research Updates (2024-2026)

[Shen Y et al., Mol Neurobiol (2024 Jul)](https://pubmed.ncbi.nlm.nih.gov/38087172/)

References

Cecchini G, Function and structure of Complex II of the respiratory chain (2003)

Rustin P, Lebon R, Touati G, et al, Biochemical and molecular investigation of succinate dehydrogenase deficiency (2002)

Ackrell BA, Cytopathies involving mitochondrial complex II (2001)

Sun F, Huo X, Zhai Y, et al, Crystal structure of mitochondrial respiratory membrane protein Complex II (2005)

Rutter J, Winge DR, Schiffman JD, Succinate dehydrogenase - assembly, regulation and role in disease (2010)

Wallace DC, Mitochondrial diseases in man and mouse (1999)

Browne SE, Bowling SP, Baik MJ, et al, Metabolic dysfunction in familial, but not sporadic, Huntington's disease (1999)

Gu M, Cooper JM, Taanman JW, Schapira AH, Mitochondrial DNA transmission of the mitochondrial genome in human disease (1998)

Lin MT, Beal MF, Mitochondrial dysfunction and oxidative stress in neurodegenerative diseases (2006)

Paschen SA, Uziel G, Ferraris PC, et al, Leigh syndrome associated with a novel mutation in the SDHAF1 gene (2012)

Ricketts CJ, Minton JA, Samuel J, et al, Succinate dehydrogenase kidney paraganglioma: a disease with multiple genetic drivers (2021)

Bayley JP, Devilee P, Tischkowitz MD, The genetics of paragangliomas and pheochromocytoma (2010)

📖 View canonical wiki page →

Mitochondrial Complex II (Succinate Dehydrogenase)

Mitochondrial Complex II (Succinate Dehydrogenase)

Introduction

Complex II (Succinate Dehydrogenase) Pathway

Overview

Mitochondrial Complex II (Succinate Dehydrogenase)

Introduction

Complex II (Succinate Dehydrogenase) Pathway

Overview

Structure

Water-Soluble Catalytic Domain (Matrix-facing)

Membrane-Anchoring Domain (Integral membrane)

Prosthetic Groups

Function

Catalytic Activity

Key Characteristics

Regulation

Transcriptional Regulation

Post-Translational Regulation

Allosteric Regulation

Neurodegeneration Relevance

Leigh Syndrome

Hereditary Paraganglioma-Pheochromocytoma Syndrome

Huntington's Disease (HD)

Alzheimer's Disease (AD)

Parkinson's Disease (PD)

Amyotrophic Lateral Sclerosis (ALS)

Therapeutic Implications

Potential Therapeutic Strategies

Challenges

See Also

Background

External Links

Confidence Assessment

Recent Research Updates (2024-2026)

References